These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27815067)

  • 41. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapy of lipodystrophy: no clear answers to clinical questions].
    Volkert R
    Dtsch Med Wochenschr; 2001 Dec; 126(49):A1118. PubMed ID: 11791516
    [No Abstract]   [Full Text] [Related]  

  • 43. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 45. HIV-associated asymmetric lipodystrophy syndrome.
    Quiros-Roldan E; Moretti F; Torti C; Casari S; Prestini K; Carosi G
    Rev Clin Esp; 2004 Mar; 204(3):177. PubMed ID: 15025990
    [No Abstract]   [Full Text] [Related]  

  • 46. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 48. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART.
    Guaraldi G; Murri R; Orlando G; Orlandi E; Sterrantino G; Borderi M; Grosso C; Cattelan AM; Nardini G; Beghetto B; Antinori A; Esposito R; Wu AW
    HIV Clin Trials; 2003; 4(2):99-106. PubMed ID: 12671777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-related lipodystrophy in Africa and Asia.
    Womack J
    AIDS Read; 2009 Apr; 19(4):131-9, 148-52. PubMed ID: 19388180
    [No Abstract]   [Full Text] [Related]  

  • 50. Update on HIV/HAART associated morphologic and metabolic abnormalities.
    Falutz J
    Forum Nutr; 2003; 56():158-62. PubMed ID: 15806844
    [No Abstract]   [Full Text] [Related]  

  • 51. HAART-associated body habitus and metabolic changes, Part 1.
    Liss M; Boyle BA
    AIDS Read; 2000 Nov; 10(11):622, 629-31. PubMed ID: 11186180
    [No Abstract]   [Full Text] [Related]  

  • 52. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART.
    Trinca JR; Sprinz E; Lazzaretti RK; Hutz MH; Kuhmmer R; de Almeida S; Tibola A; Meirelles GB; Arena-de-Souza RC; Mattevi VS
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):299-305. PubMed ID: 20964254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-Associated facial lipoatrophy: from the advent to current knowledge.
    Soares FM; Costa IM
    An Bras Dermatol; 2011; 86(5):843-62; quiz 863-4. PubMed ID: 22147023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
    Calmy A; Hirschel B; Hans D; Karsegard VL; Meier CA
    AIDS; 2003 Mar; 17(5):770-2. PubMed ID: 12646807
    [No Abstract]   [Full Text] [Related]  

  • 58. Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy.
    Florindo AA; de Oliveira Latorre Mdo R; Jaime PC; Segurado AA
    Int J STD AIDS; 2007 Oct; 18(10):692-6. PubMed ID: 17990379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.